Subkutan infliximab formulation CT-P13 appears to be useful in the treatment of patients with moderately serious active ulcerative colitis , the Data from Phase III study Liberty-UC shows that the drug performs better at multiple extreme points. “Clinical remission, clinical response, endoscopic-histological mucosal improvement and 54 weeks based on corticosteroid remission based on intravenous induction CT-P13 with CT-P13 on CT-P13 on CT-P13, one of the Writers' Works on CT-P13, DDW 2023, DDW 2023Speaking in New York, New York Sinai Mountain of ICAHN Faculty of Medicine.Bruce Sands. The Liberty-UC included 548 UC patients with a modified swimsuit score of 5-9 and ≥2 points endoscopic subsidies. These patients were treated with CT-P13 IV 5 mgkg as induction treatment in 0, 2 and 6 weeks.10.438 patients per week responded to the CT-P13 IV induction dose and then CT-P13 SC 120 mg to get care treatment with randomly appointed to get care treatment every 2 weeks until 54 weeks. The clinical response was defined as a decrease in the swimsuit score of at least 2 points, and accompanied by at least 30 percent of the base line, at least 1 point rectal bleeding sub -score or 0 or 1 point in the absolute rectal bleeding subtitle. The clinical remission rate of the 54th week was the primary final point, CT-P13 SC with placebo and 43.2 percent with 20.8 percent ., 31.3 percent against 7, endoscopic-histological mucosal improvement and 35.7 percent for 36.7 percent against 16.7 percent and 16.7 percent for the inter-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-non-complic2023, summary 1701] "CT-P13 SC groove concentration of the CT-P13 SC, until the 54th week of the target therapeutic concentration level was maintained well on a good way," he said. He added that the median concentrations of inflammatory biobelirties are kept low in the CT-P13 SC group of C-Reactive protein and fecal resumption, and that the placebo group is constantly lower than the placebo group. As for security, the use of CT-P13 SC in the care environment was well tolerated, showing the lack of clinically significant differences in the frequencies of adverse events due to treatment between sands, research drugs and placebo . The most common TEAE was the infection that occurred in 28.0 percent of patients in the CT-P13 SC group and 25.7 percent in the placebo group.) Percentage and 2 percent percentage and 2.1 percent) .TEAES, 3.4 percent of patients in CT-P13 SC and 2.9 percent of the placeboded caused the treatment of treatment.No death was reported. CT CT-P13 subkutan infliximab formulation was developed to provide patients with a suitable option for treatment. Previous studies have shown the comparable activity and security of the CT-P13 IV of inflammatory bowel disease and rheumatoid arthritis.2021;160 2340-2353; Rheumatology 2021;60 2277-2287] Liberty-UC's results show that “CT-P13 SC provides both a solid clinical benefit and comfort of SC application to patients with moderately serious active UC.”